Literature DB >> 2845483

Evidence for LTB4/12-HETE binding sites in a human epidermal cell line.

E Gross1, T Ruzicka, C Mauch, T Krieg.   

Abstract

We identified leukotriene B4 (LTB4)/12-hydroxyeicosatetraenoic acid (12-HETE) binding sites in a squamous cell cancer-derived human epidermal cell line. Analysis of the binding data revealed a single class of binding sites with a dissociation constant of 0.16 microM and a Bmax of 3.8 x 10(6) sites per cell. Competitive binding assays with various eicosanoids at 37 degrees C showed nearly equal binding of 12(S)-HETE, 12(R)-HETE and LTB4. 5(S)-HETE and LTB4-analogs bound with lesser affinity. Specific LTB4 binding at 37 degrees C could also be demonstrated in freshly isolated normal human keratinocytes. Since lipoxygenase-derived eicosanoids are thought to play an important role in hyperproliferative and inflammatory skin diseases, the identification of LTB4/12-HETE binding sites in keratinocytes could have implications for the development of new drugs controlling these disease processes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845483     DOI: 10.1016/0090-6980(88)90101-3

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  3 in total

1.  Leukotriene A4 hydrolase in peripheral leukocytes of patients with atopic dermatitis.

Authors:  H Okano-Mitani; K Ikai; S Imamura
Journal:  Arch Dermatol Res       Date:  1996-04       Impact factor: 3.017

Review 2.  Fatty acid modulation of tumor cell-platelet-vessel wall interaction.

Authors:  Y Q Chen; B Liu; D G Tang; K V Honn
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

3.  Antiinflammatory effects of second-generation leukotriene B4 receptor antagonist, SC-53228: impact upon leukotriene B4- and 12(R)-HETE-mediated events.

Authors:  D J Fretland; C P Anglin; M Bremer; P Isakson; D L Widomski; S K Paulson; S H Docter; S W Djuric; T D Penning; S Yu
Journal:  Inflammation       Date:  1995-04       Impact factor: 4.092

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.